SID is diagnosed in individuals without a prior history of T2DM, who meet standard diagnostic criteria for diabetes during glucocorticoid exposure (1, 2)
The active ingredient, semaglutide, belongs to a class of drugs called GLP-1 receptor agonists
Compounded GLP-1 Peptides: Evidence, Risks, and the Regulatory Picture The clinical evidence for semaglutide and tirzepatide is substantial and comes from FDA-approved drugs, not compounded versions
To help users identify trustworthy providers, Best GLP1 outlines important green flags, including licensed physician review, transparent pricing, responsive customer support, legitimate patient reviews, easy cancellation policies, and medication sourced through appropriate pharmacies
These include improving vascular function, reducing systemic inflammation, enhancing coronary microvascular function, and mitigating comorbid conditions like metabolic dysfunction-associated steatotic liver disease (MASLD) and chronic kidney disease (CKD)
The most common adverse events associated with tirzepatide are gastrointestinal symptoms, including nausea and vomiting, which are similar to those observed with GLP-1 RAs [72, 73]